Haemonetics Corporation (HAE) Stock Analysis
Healthcare · Medical Devices
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including... Read more
TrendMatrix rates Haemonetics Corporation (HAE) as Hold with moderate confidence. The stock trades at $55.93 with +33.0% upside to the $74.38 price target. Overall score: 5.7/10 across 10 analysis dimensions. Reward/risk ratio: 7.5:1.
Passes 3/5 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Haemonetics Corporation (HAE) as Hold with moderate confidence. Score 5.7/10.
Take-profit target: $74.38 (+33.0% upside). Reward/risk ratio: 7.5:1. Stop-loss: $53.47.
Leverage penalty (D/E 1.3): -0.5; Negative momentum; Below 200-day MA.
Haemonetics Corporation trades at a P/E of 15.6 (forward 10.6). TrendMatrix value score: 8.2/10. Verdict: Hold.
15 analysts cover HAE with a consensus score of 3.9/5. Average price target: $88.
What does Haemonetics Corporation do?Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the...
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.